Chalazion (cyst): Symptoms, pictures, causes, and treatment

Modulating Conjunctival Wound Healing

Thylefors B, Negrel A . The global impact of glaucoma. Bull World Health Org 1994;72:323–6

CAS  PubMed  PubMed Central  Google Scholar 

Foster A, Johnson G . Magnitude and causes of blindness in the developing world. Int Ophthalmol 1990;14:135–40

Article  CAS  PubMed  Google Scholar 

Quigley H . Number of people with glaucoma worldwide [see comments]. Br J OphthalmoI 1996;80:389–93

Article  CAS  Google Scholar 

Sommer A . Glaucoma: facts and figures. Doyne Lecture. Eye 1996;10:295–301

Article  PubMed  Google Scholar 

Jay J . Rational choice of therapy in primary open angle glaucoma. Eye 1992;6:243–7

Article  PubMed  Google Scholar 

Migdal C, Gregory W, Hitchings R Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651–6

Article  CAS  PubMed  Google Scholar 

Addicks E, Quigley H, Green W, Robin A . Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795–8

Article  CAS  PubMed  Google Scholar 

Hitchings R, Grierson I . Clinicopathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK 1983;103:84–8

PubMed  Google Scholar 

Stamper R, McMenemy M, Lieberman M . Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992;114:544–53

Article  CAS  PubMed  Google Scholar 

Parrish R, Minckler D . 'Late endophthalmitis': filtering surgery time bomb? Ophthalmology 1996:103:1167–8.

Article  CAS  PubMed  Google Scholar 

Jampel H, Pasquale L, Dibernardo C Hypotony maculopathy following trabeculectomy with mitomycin C Arch Ophthalmol 1992;110:1049–50.

Article  CAS  PubMed  Google Scholar 

The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol 1989;108:625–35

Katz G, Higginbotham E, Lichter P, Skuta G, Musch D, Bergstrom T, et al . Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery: extended follow-up. Ophthalmology 1995;102:1263–9

Article  CAS  PubMed  Google Scholar 

Kitazawa Y, Kawase K, Matsushita H, Minobe M . Trabeculectomy with mitomycin: a comparative study with fluorouracil. Arch Ophthalmol 1991;109:1693–8

Article  CAS  PubMed  Google Scholar 

Lamping K, Belkin J . 5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995;102:70–5

Article  CAS  PubMed  Google Scholar 

Khaw P, Doyle J, Sherwood M, Grierson I, Schultz G, McGorray S . Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol 1993;111:263–7

Article  CAS  PubMed  Google Scholar 

Crowston J, Akbar A, Constable P, Occleston N, Daniels J, Khaw P . Antimetabolites-induced apoptosis in Tenon' capsule fibroblasts. Invest Ophthalmol Vis Sci 1998;39:449–54

CAS  PubMed  Google Scholar 

Singer A, Clarke RA . Cutaneous wound healing. N Engl J Med 1999;341:738–46

Article  CAS  PubMed  Google Scholar 

Clark R, Henson P . The molecular and cellular biology of wound repair. New York: Plenum Press, 1988.

Reichel M, Ali R, Thrasher A, Hunt D, Bhattacharya S, Baker D . Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Ther 1998;5:1038–46

Article  CAS  PubMed  Google Scholar 

Khaw P, Occleston N, Schultz G, Grierson I, Sherwood M, Larkin G . Activation and suppression of fibroblast function. Eye 1994;8:188–95

Article  PubMed  Google Scholar 

Occleston N, Tarnuzzer R, Munro P, Ravetto P, Ali R, Schultz G, et al . Inhibition of matrix metalloproteinase activity inhibits Tenon' capsule fibroblast mediated collagen contraction. Invest Ophthalmol Vis Sci 1995;36:S877.

Google Scholar 

Scott K, Wood E, Karran E . A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett 1998;441:137–40

Article  CAS  PubMed  Google Scholar 

Desmouliere A, Redard M, Darby I, Gabbiani G . Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56..6.

Google Scholar 

Liu B, Connolly M . The pathogenesis of cutaneous fibrosis. Semin Cutan Med Surg 1998;17:3–11

Article  CAS  PubMed  Google Scholar 

Fini E . Keratocyte and fibroblast phenotypes in the repairing cornea. Prog Retinal Eye Res 1999;18:529–51

Article  CAS  Google Scholar 

Broadway D, Grierson I, O'Brien C, Hitchings R . Adverse effects of topical anti-glaucomatous medication regimens. I. Effect on the cell profile of the conjunctiva. Arch Ophthalmol 1994;112:1446–54

Article  CAS  PubMed  Google Scholar 

Broadway D, Grierson I, O'Brien C, Hitchings R . Adverse effects of topical antiglaucoma medication regimens. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1437–45

Article  CAS  PubMed  Google Scholar 

Broadway D, Grierson I, O'Brien C, Hitchings RA . Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch OphthalmoI 1996;114:262–7

Article  CAS  Google Scholar 

Gwynn D, Stewart W, Pitts R, McMillian T, Hennis H . Conjunctival structure and cell counts and the results of filtering surgery. Am J Ophthalmol 1993;116:464–8

Article  CAS  PubMed  Google Scholar 

Nuzzi R, Vercelli A, Finazzo C, Cracco C . Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatments: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 1995;233:154–62

Article  CAS  PubMed  Google Scholar 

Occleston N, Alexander R, Mazure A, Larkin G, Khaw P . Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction. Invest Ophthalmol Vis Sci 1994;35:3681–90

CAS  PubMed  Google Scholar 

Occleston N, Daniels J, Tarnuzzer R, Sethi K, Alexander R, Bhattacharya S, et al . Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behaviour. Invest Ophthalmol Vis Sci 1997;38:1998–2007

CAS  PubMed  Google Scholar 

Daniels J, Occleston N, Crowston J, Khaw P . Effects of antimetabolite induced cellular growth arrest on fibroblast-fibroblast interactions. Exp Eye Res 1999;69:117–27

Article  CAS  PubMed  Google Scholar 

Waterman-Storer C, Worthylake R, Liu B, Burridge K, Salmon E . Microtubule growth activates Rac1 to promote lamellipodial protrusion in fibroblasts. Nature Cell BioI 1999;1:45–50

Article  CAS  Google Scholar 

Metcalfe R, Weetman A . Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmology. Clin Endocrinol 1994;40:67–72

Article  CAS  Google Scholar 

Joseph J, Grierson I, Hitchings R . Taxol, cytochalasin B and colchicine effects on fibroblast migration and contraction: a role in glaucoma filtration surgery? Curr Eye Res 1989:8:203–15.

Article  CAS  PubMed  Google Scholar 

Jampel H, Moon J . The effect of paclitaxel powder on glaucoma filtration surgery in rabbits. J Glaucoma 1998;7:170–7

CAS  PubMed  Google Scholar 

Jampel H, Thibault D, Leong K, Uppal P, Quigley H . Glaucoma filtration surgery in non-human primates using taxol and etoposide in polyanhydride carriers. Invest Ophthalmol Vis Sci 1993;34:3076–83

CAS  PubMed  Google Scholar 

Blagosoklonny M, Fojo T . Molecular effects of paclitaxel: myths and reality. Int J Cancer 1999;83:151–6

Article  Google Scholar 

Pleass R, Khaw P . Inhibition of remodelling and contraction in ocular wound healing. Keystone Symposium: Ocular cell and molecular biology, Colorado, 1999:37.

Daniels J, Khaw P . Synthetic matrix metalloproteinase inhibitor reduces contraction of cultured ocular tissue. Eur J Plast Surg 2000;in press.

Pilcher B, Wang M, Qin X, Parks W, Senior R, Welgus H . Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann N Y Acad Sci 1999;878:12–24

Article  CAS  PubMed  Google Scholar 

Skotnicki J, Zask A, Nelson F, Albright J, Levin J . Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci 1999;878:61–72

Article  CAS  PubMed  Google Scholar 

De B, Natchus M, Cheng M, Pikul S, Almstead N, Taiwo Y, et al . The next generation of MMP inhibitors: design and synthesis. Ann N Y Acad Sci 1999;878:40–60

Article  CAS  PubMed  Google Scholar 

McGuigan L, Mason R, Sanchez R, Quigley H . D-Penicillamine and beta-aminoproponitrile effects on experimental filtering surgery. Invest Ophthalmol Vis Sci 1987;28:1625–9

CAS  PubMed  Google Scholar 

Blumenkranz M, Ophir A, Claflin A, Hajek A . Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol 1982;94:458–67

Article  CAS  PubMed  Google Scholar 

Blumenkranz M, Hartzer M, Hajek A . Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol 1987;105:396–9

Article  CAS  PubMed  Google Scholar 

Chen C . Enhanced intraocular pressure controlling effectiveness of trabeculectomy by local application of mitomycin-C. Trans Asia Pacif Acad Ophthalmol 1983;9:172–7

Google Scholar 

Doyle J, Sherwood M, Khaw P, McGoray S, Smith M . Intraoperative 5-fluorouracil for filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1993;34:3313–9

CAS  PubMed  Google Scholar 

Khaw P, Sherwood M, MacKay S, Rossi M, Schultz G . Five- minute treatments with fluorouracil, floxuridine and mitomycin have long-term effects on human Tenon' capsule fibroblasts. Arch Ophthalmol 1992;110:1150–4

Article  CAS  PubMed  Google Scholar 

Honjo M, Tanihara H, Inatani M, Honda Y . Mitomycin C trabeculectomy in eyes with cicatricial conjunctiva. Am J Ophthalmol 1998;126:823–4

Article  CAS  PubMed  Google Scholar 

Ali-Hazmi A, Zwann J, Awad A, Al-Mesfer S, Mullaney P . Effectiveness and complications of mitomycin C use during pediatric glaucoma surgery. Ophthalmology 1998;105:1915–20

Article  Google Scholar 

Beck A, Wilson W, Lynch M, Lynn M, Noe R . Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Am J Ophthalmol 1998;126:648–57

Article  CAS  PubMed  Google Scholar 

Khaw P . What is the best primary surgical treatment for the infantile glaucomas? Br J Ophthalmol 1996:80:495–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khaw P, Wilkins M, Shah P . Glaucoma surgery. In: Easty D, Sparrow J, editors. Oxford textbook of ophthalmology. Oxford: Oxford University Press, 1999:1211–39.

Google Scholar 

Shin D, Reed S, Swords R, Reed A, Simone P, Birt C . Cellulose sponge punch for controlled mitomycin application. Arch Ophthalmol 1994;112:1624–5

Article  CAS  PubMed  Google Scholar 

Wilkins M, Occleston N, Kotecha A, Waters L, Khaw P . Sponge delivery parameters and tissue levels of 5-fluorouracil. Br J Ophthalmol 2000;84:92–7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehel E, Weber M, Stork L, Pechereau A . A novel method for controlling the quantity of mitomycin-C applied during filtering surgery for glaucoma. J Ocul Pharmacol Ther 1998;14:491–6

Article  CAS  PubMed  Google Scholar 

Cordeiro M, Constable P, Alexander R, Bhattacharya S, Khaw P . The effect of varying mitomycin-C treatment area in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1997;38:1639–46

CAS  PubMed  Google Scholar 

Miller M, Rice N . Trabeculectomy combined with beta irradiation for congenital glaucoma. Br J Ophthalmol 1991;75:584–90

Article  CAS  PubMed  PubMed Central  Google Scholar 

Constable P, Crowston J, Occleston N, Cordeiro M, Khaw P . Long term growth arrest of human Tenon' fibroblasts following single applications of beta radiation. Br J Ophthalmol 1998;82:448–52

Article  CAS  PubMed  PubMed Central  Google Scholar 

Constable P, Cordeiro M, Crowston J, Khaw P . The effects of single doses of beta irradiation on bleb survival and morphology in a rabbit model of filtration surgery. Invest Ophthalmol Vis Sci 1998;39 (Suppl): abstract no. 3192.

Singh K, Group PTAS . Intraoperative 5-fluorouracil (5FU) vs mitomycin C (MMC): the primary trabeculectomy antimetabolite study. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no.19.

Palmberg P, Escalona E, Norris E, Schiffman J . Long-term follow-up primary filtering surgery with mitomycin or 5-fluorouracil. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no. 1416.

Finley C, Cantor L, Wudunn D, Hoop J, Lakhani V, Alvi N . Comparison of intraoperative 5-fluorouracil versus mitomycin C at six and twelve months in primary trabeculectomy. Invest Ophthalmol Vis Sci 1999;40 (Suppl): abstract no. 5098.

Al-Aswad L, Huang M, Netland P . Inhibition of Tenon' fibroblast proliferation and enhancement of filtration surgery in rabbits with cytosine arabinoside. J Ocul Pharmacol 1999;15:41–9

Article  CAS  Google Scholar 

Denk P, Knorr M . In vitro effect of ascorbic acid on the proliferation of bovine scleral and Tenon' capsule fibroblasts. Eur J Ophthalmol 1998;8:37–41

Article  CAS  PubMed  Google Scholar 

Maignen F, Tilleul P, Billardon C, Xu-Van Opstal W, Pelaprat D, Elena P, et al. Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex vivo model. J Ocul Pharmacol Ther 1996;12:289–98

Article  CAS  PubMed  Google Scholar 

Akimoto M, Hangai M, Okazaki K, Kogishi J, Honda Y, Kaneda Y . Growth inhibition of cultured human Tenon' fibroblastic cells by targeting the E2F transcription factor. Exp Eye Res 1998;67:395–401

Article  CAS  PubMed  Google Scholar 

Wahl S . Glucocorticoids and wound healing. In: Scleimer RP, Claman D, editors. Antiinflammatory steroid action: basic and clinical aspects. New York: Academic Press, 1989:280–302.

Google Scholar 

Miller M, Grierson I, Unger W, Hitchings R . The effect of topical dexamethasone and preoperative beta irradiation on a model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg 1990;21:44–54

CAS  PubMed  Google Scholar 

Araujo S, Spaeth G, Roth S, Starita R . A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy. Ophthalmology 1995;102:1753–9

Article  CAS  PubMed  Google Scholar 

Giangiacomo J, Dueker D, Adelstein E . The effect of preoperative subconjunctival triamcinolone administration on glaucoma filtration. Arch Ophthalmol 1986;104:838–41

Article  CAS  PubMed  Google Scholar 

Nguyen K, Lee D . Effect of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblasts. Invest Ophthalmol Vis Sci 1992;33:2693–701

CAS  PubMed  Google Scholar 

Migdal C, Hitchings R . The developing bleb: effect of topical antiprostaglandins on the outcome of glaucoma fistulizing surgery. Br J Ophthalmol 1983;67:655–60

Article  CAS  PubMed  PubMed Central  Google Scholar 

Snyder R, Lambrou F, Williams G . Intraocular fibrinolysis with recombinant human tissue plasminogen activator: experimental treatment in a rabbit model. Arch Ophthalmol 1987;105:1277–80

Article  CAS  PubMed  Google Scholar 

Lee P, Myers K, Hsieh M, Wood E, Hotaling D . Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA). J Ocul Pharmacol Ther 1995;11:227–32

Article  CAS  PubMed  Google Scholar 

Azuara-Blanco A, Wilson R . Intraocular and extraocular bleeding after intracameral injection of tissue plasminogen activator. Br J Ophthalmol 1998;82;1345–6.

Lundy D, Sidoti P, Winarko T, Minckler D, Heuer D . Tissue plasminogen activator after glaucoma surgery: indications, effectiveness, and complications. Ophthalmology 1996;103:274–82

Article  CAS  PubMed  Google Scholar 

Zwann J, Latimer W . Topical tissue plasminogen activator appears ineffective for the clearance of intraocular fibrin. Ophthalmic Surg Lasers 1998;29:476–83

Article  Google Scholar 

WuDunn D . Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery. Am J Ophthalmol 1997;124:693–5

Article  CAS  PubMed  Google Scholar 

Bramsen T . A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex. Acta Ophthalmol 1978;56:998–1005

Article  CAS  Google Scholar 

Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D . Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808–12

Article  CAS  PubMed  Google Scholar 

D'Amore P . Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 1992;6:1–8

Article  CAS  PubMed  Google Scholar 

Favard C, Moukadiri H, Dorey C . Praloran V, Plouet J. Purification and biological properties of vasculotropin a new angiogenic cytokine. Biol Cell 1991;73:1–6

Article  CAS  PubMed  Google Scholar 

Liu J, Razani B, Tang S, Terman B, Ware J, Lisanti M . Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. J Biol Chern 1999;274:15781–5

Article  CAS  Google Scholar 

Furlong R . The biology of hepatocyte growth factor/scatter factor. Bioessays 1992;14:613–7

Article  CAS  PubMed  Google Scholar 

Paper D . Natural products as angiogenesis inhibitors. Planta Med 1998;64:686–95

Article  CAS  PubMed  Google Scholar 

Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Skukhatme V . Endostatin induces endothelial cell apoptosis. J Biol Chern 1999;274:11721--6.

Article  CAS  Google Scholar 

O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, et al . Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997;88:277–85

Article  CAS  PubMed  Google Scholar 

Liekens S, Neyts J, Degreve B, De Clercq E . The sulfonic acid polymers PAMPS poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. Oncol Res 1997;9:173–91

CAS  PubMed  Google Scholar 

Wong J, Wang N, Miller J, Schuman J . Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994;58:439–51

Article  CAS  PubMed  Google Scholar 

Akbar A, Salmon M . Cellular environments and apoptosis: tissue microenvironments control activated T cell death. Immunol Today 1997;18:72–6

Article  CAS  PubMed  Google Scholar 

Ellerby H, Arap W, Ellerby L, Kain R, Andrusiak R, Del Rio G, et al . Anti-cancer activity of targeted pro-apoptosic peptides. Nature 1999;5:1032–8

CAS  Google Scholar 

Gillies M, Brooks A, Young S, Gillies B, Simpson J, Goldberg I . A randomized phase II trial of interferon-alpha 2b versus 5-fluorouracil after trabeculectomy. Aust N Z J Ophthalmol 1999;27:37–44

Article  CAS  PubMed  Google Scholar 

Nguyen K, Hoang A, Lee D . Transcriptional control of human Tenon' capsule fibroblast collagen synthesis in vitro by gamma-interferon. Invest Ophthalmol Vis Sci 1989;35:3064–70

Google Scholar 

Duncan M, Berman B . Differential regulation of collagen, glycosaminoglycan, fibronectin, and collagenase activity production in cultured human adult dermal fibroblasts by interleukin 1-alpha and beta and tumor necrosis factor- alpha and beta. J Invest Dermatol 1989;92:699–706

Article  CAS  PubMed  Google Scholar 

Berman B, Duncan M . Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989;21:694–702

Article  CAS  PubMed  Google Scholar 

Kahan A, Amor B, Menkes C, Strauch G . Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 1989;87:273–7

Article  CAS  PubMed  Google Scholar 

Petri J, Schurk S, Gebauer S, Haustein U . Cyclosporine A delays wound healing and apoptosis and suppresses activin beta-A expression in rats. Eur J Dermatol 1998;8:104–13

CAS  PubMed  Google Scholar 

Nuzzi R, Cerruti A, Finazzo C . Cyclosporine C: a study of wound-healing modulation after trabeculectomy in rabbit. Acta Ophthalmol Scand 1998;227 (Suppl):48–9.

Google Scholar 

Massague J . The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597–641

Article  CAS  PubMed  Google Scholar 

Roberts A, Sporn M, Assoian R, Smith JJ Roche N . Transforming growth factor beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167–71

Article  CAS  PubMed  PubMed Central  Google Scholar 

Critchlow M, Bland Y, Ashhurst D . The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone 1995;16:521–7

Article  CAS  PubMed  Google Scholar 

Cordeiro M, Reichel M, Gay J D'Esposita F, Alexander R, Khaw P . TGF-131, -132 and -133 in vivo: effects on normal and mitomycin-C modulated conjunctival scarring. Invest Ophthalmol Vis Sci 1999;40:1975–82

CAS  PubMed  Google Scholar 

Cordeiro M, Bhattacharya S, Schultz G, Khaw P . TGF-131, -132 and -133 in vitro: biphasic effects on Tenon' fibroblast contraction, proliferation and migration. Invest Ophthalmol Vis Sci 2000;41:756–63

CAS  PubMed  Google Scholar 

Connor T, Roberts A, Sporn M, Danielpour D, Dart L, Michels R, et al . Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989;83:1661–6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jampel H, Roche N, Stark W, Roberts A . Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990;9:963–9

Article  CAS  PubMed  Google Scholar 

Shah M, Foreman D, Ferguson M . Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994;107:1137–57

Article  CAS  PubMed  Google Scholar 

Shah M, Foreman D, Ferguson M . Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108:985–1002

Article  CAS  PubMed  Google Scholar 

Cordeiro M, Gay J Khaw P . Human anti-TGF-132 monoclonal antibody: a new anti-scarring agent for glaucoma filtration surgery. Invest Ophthalmol Vis Sci 1999;40:2225–34

CAS  PubMed  Google Scholar 

Wu-Pong S, Weiss T, Hunt C . Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev 1994;4:155–63

Article  CAS  PubMed  Google Scholar 

Adachi S, Maruyama T, Kondo T, Todoroki T, Fukao K . The prevention of postoperative intraperitoneal adhesions by tranilast, N-(3',4'-dimethoxycinnamoyl)anthranilic acid. Surg Today 1999;29:51–4

Article  CAS  PubMed  Google Scholar 

Ito S, Sakamoto T, Tahara Y, Goto Y, Akazawa K, Ishibashi T, et al . The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1999;237:691–6

Article  CAS  PubMed  Google Scholar 

Takehana Y, Kurokawa T, Kitamura T, Tsukahara Y, Akahane S, Kitazawa M, et al . Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest Ophthalmol Vis Sci 1999;40:459–66

CAS  PubMed  Google Scholar 

Furukawa H, Nakayasu K, Gotoh T, Watanabe Y, Takano T, Ishikawa T, et al . Effect of topical tranilast and corticosteroids on subepithelial haze after photorefractive keratectomy in rabbits. J Refract Surg 1997;13 (Suppl):S457–8.

CAS  PubMed  Google Scholar 

Chihara E, Dong J, Ochiai H . Effect of TGF-131 suppressor Tranilast on filtering bleb and lOP after glaucoma surgery. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no. 5104.

Kim H, Peterson T, Barnes S . Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signalling pathways. Am J Clin Nutr 1998;68 (Suppl):S1418–25.

Article  Google Scholar 

Krott R, Lebek J Grisanti S, Luke C, Esser P, Kriegelstein G . Antiproliferative effect of Genistein in cultured human Tenon-fibroblasts. Invest Ophthalmol Vis Sci 1999;40 (Suppl):abstract no. 5117.

Mietz H, Chevez-Barrios P, Feldman R, Lieberman M . Suramin inhibits wound healing following filtering procedures for glaucoma. Br J Ophthalmol 1998;82:816–20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beardsley T . Making antisense. Sci Am 1992;3:107–8

Article  Google Scholar 

Fakler B, Herlitze S, Amthor B, Zenner H, Ruppersberg J . Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J Biol Chern 1994;269:16187–94

Article  CAS  Google Scholar 

Sugawa N, Ueda S, Nakagawa H, Nishino H, Nosaka K, Iwashima A, et al . An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neurooncol 1998;39:237–44

Article  CAS  PubMed  Google Scholar 

Wilson C, Szostak J . In vitro evolution of a self-alkylating ribozyme. Nature 1995;374:777–82

Article  CAS  PubMed  Google Scholar 

Moore M . Exploration by lamp light. Nature 1995;374:766–7

Article  CAS  PubMed  Google Scholar 

Bartel D, Szostak J . Isolation of new ribozymes from a large pool of random sequences. Science 1993;261:1411–8

Article  CAS  PubMed  Google Scholar 

Altman S . RNA enzyme-directed gene therapy. Proc Natl Acad Sci USA 1993;90:10898–900

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dorai T, Kobayashi H, Holland J Ohnuma T . Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol 1994;46:437–44

CAS  PubMed  Google Scholar 

Drenser K, Timmers A, Hauswirth W, Lewin A . Ribozyme-targeted destruction of RNAs associated with ADRP. Invest Ophthalmol Vis Sci 1998;39:681–9

CAS  PubMed  Google Scholar 

Lewin A, Drenser K, Hauswirth W, Nishikawa S, Yasumura D, Flannery J, et al . Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nature Med 1998;4:967–71

Article  CAS  PubMed  Google Scholar 

Ren X, Schultz G . Reduction of transforming growth factor beta-1 protein in cells transfected with plasmids expressing hammerhead and hairpin ribozymes. Invest Ophthalmol Vis Sci 1999;40 (Suppl):46.

Google Scholar 

Medications And Their Potential To Cause Increase 'Conjunctival Congestion'

List of Drugs that may cause 'Conjunctival congestion'

Advertisement

Updated on November 16, 2023 This section presents medications that are known to potentially lead to 'Conjunctival congestion' as a side effect." It's important to note that mild side effects are quite common with medications. Please be aware that the drugs listed here are individual medications and may be part of a broader combination therapy. This information is meant to be a helpful resource but should not replace professional medical advice. If you're concerned about 'Conjunctival congestion', it's best to consult a healthcare professional. In addition to 'Conjunctival congestion', other symptoms or signs might better match your side effect. We have listed these below for your convenience. If you find a symptom that more closely resembles your experience, you can use it to identify potential medications that might be the cause.

Advertisement

proparacaine Find drugs that can cause other symptoms like 'Conjunctival congestion' Blepharoconjunctivitis , Chemical conjunctivitis , Chronic conjunctivitis , Conjunctival bleb , Conjunctival cyst , Conjunctival discharge , Pterygium , Conjunctival disorder , Conjunctival follicles , Conjunctival irritation , Conjunctival ulcer , Conjunctival xerosis , Conjunctivitis , Conjunctivitis allergic , Conjunctivitis bacterial , Conjunctivitis exacerbated , Conjunctivitis infective , Conjunctivitis papillary , Follicular conjunctivitis , Keratoconjunctivitis , Other conjunctivitis , Subconjunctival cyst References

https://www.Fda.Gov/drugs/information-consumers-and-patients-drugs/finding-and-learning-about-side-effects-adverse-reactions

https://nctr-crs.Fda.Gov/fdalabel/ui/search

https://dailymed.Nlm.Nih.Gov/dailymed/

Search Side effects by name Recently Added Drugs

Oral rehydration salts are prescribed when there is a loss of body fluids in: Aged people who have a lesser sense of thirst.

Proparacaine ophthalmic is an ophthalmic medication that exerts anesthetic action instantaneously.

Barium sulphate is opaque to X-rays as it has a high molecular density.

Atazanavir is a protease inhibitor, and its activity gets amplified when taken in combination with activity enhancers such as Ritonavir.

Carboxymethylcellulose is prescribed for treating dry eyes.

Activated charcoal is prescribed for the treatment of moderate to severe cases of poisoning where gastrointestinal decontamination (removal of toxin from gastrointestine) is needed.

In the treatment of acute promyelocytic leukemia, arsenic trioxide has been known to display strong anti-tumor effects with few toxic effects.

Abacavir, Dolutegravir,and Lamivudine combination tablets are prescribed to HIV-infected patients.

Algeldrate is prescribed as a gastric antacid in adults.

Amtolmetin guacil is prescribed for Rheumatoid arthritis in Adults and Children above 2 years .

↑

New Forecast For Bullous Pemphigoid Therapies Market 2024: Set To Achieve Significant Value By 2030

(MENAFN- The Express Wire) Bullous Pemphigoid Therapies Market Insights 2023: Watch on share analysis of the key market participants in global Bullous Pemphigoid Therapies market, their product portfolio, Growth Rate, research priorities, and forecast to 2030.

Bullous Pemphigoid Therapies Market Outlook 2023-2030

The research report on the " Bullous Pemphigoid Therapies Market " [2023-2030] delves into an extensive analysis of the elements that exert their influence on the market's course. Venturing into the realm of advancements, research and development investments, evolving patterns in consumption, and the broadening array of applications that are shaping the market's trajectory, this report offers a comprehensive perspective. Furthermore, it dissects the ever-changing economic dynamics surrounding the Bullous Pemphigoid Therapies Market, poised to impart a significant impact on its path. Derived from a rigorous undertaking of primary and secondary research, this detailed market investigation culminates in a profound grasp of the Bullous Pemphigoid Therapies market's intricacies. Beyond a comprehensive depiction of current and future market aspirations, the report also undertakes a competitive scrutiny of the sector, characterized by its applications, types, and regional shifts. The report goes the extra mile in presenting an intricate portrayal of the historical and contemporary accomplishments of notable enterprises.

Between 2023 and 2030, the Global Bullous Pemphigoid Therapies Market is poised to experience substantial growth. The market has maintained a steady upward trajectory in 2021 and is projected to continue this ascent over the forecasted period, driven by the increasing implementation of strategies by prominent industry players. Ask for a Sample Report

Report Spanning across - 116 Pages

Bullous Pemphigoid Therapies Market Report Revenue by Type ( Steroid Creams, Immune Suppressants, Antibiotics ), Forecasted Market Size by Application ( Initial Phase, Active Treatment Phase, Reducing Phase, Maintenance Phase )

TOP COMPANIES/MANUFACTURERS Dominating the Global Bullous Pemphigoid Therapies Market are listed below:

Regeneron Pharmaceuticals

Sanofi

Pfizer

SUANFARMA

Tecoland Corporation

Century Pharmaceuticals

Akari Therapeutics

Immune Pharmaceuticals

Innate Pharma

AstraZeneca

Grifols

Aptalis

Medicis Pharmaceutical Corporation

Shaanxi Xiyue Pharmaceutical

Kunming Zhenhua Pharmaceutical Factory

Qinghai Pharmaceutical Factory

Get a Sample Copy of the Bullous Pemphigoid Therapies Market Report 2023

Market Analysis and Insights: Global Bullous Pemphigoid Therapies Market

Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Incidence figures are not available for most parts of the world but BP appears to be rarer in the Far East. Bullous pemphigoid is usually a disease of the elderly but it can also affect younger people and children. Both sexes are similarly affected.

The global Bullous Pemphigoid Therapies market was valued at USD million in 2020 and it is expected to reach USD million by the end of 2030, growing at a CAGR of Percent during 2021-2030. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Bullous Pemphigoid Therapies Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the market's growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2018 to 2030. This section mentions the volume of production by region from 2016 to 2030. Pricing analysis is included in the report according to each type from the year 2016 to 2030, manufacturer from 2016 to 2021, region from 2018to 2021, and global price from 2018 to 2030.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert's opinions have been taken to understand